Alan F Schatzberg MD
Director, Stanford Mood Disorders Center. Professor, Department of Psychiatry and Behavioral Sciences Stanford University Medical Center.
Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-498-5710
Fax+1 650-498-5294
Dr. Schatzberg is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Harvard Medical SchoolResidency, Psychiatry, 1969 - 1972
Lenox Hill Hospital-Northwell HealthInternship, Transitional Year, 1968 - 1969
New York University School of MedicineClass of 1968
Certifications & Licensure
CA State Medical License 1974 - 2026
MA State Medical License 1969 - 2025
American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- Women's Health Castle Connolly, 2008
- Elected Member Institute of Medicine, 2003
- Join now to see all
Clinical Trials
- Age-Related Changes in Stress Hormone Regulation Start of enrollment: 2000 Dec 01
- Clinical and Biological Characteristics of Psychotic Depression Start of enrollment: 2005 Aug 01
- Genetics of Symptomatology and Treatment Response in Psychotic Major Depression Start of enrollment: 2003 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Methodological Considerations for Interpreting Ketamine-Naltrexone Trials in Depression.Igor D Bandeira, Luke A Jelen, Jason M Tucciarone, Boris D Heifets, Carolyn I Rodriguez
The International Journal of Neuropsychopharmacology. 2025-10-02 - Esketamine Treatment for Depression in Adults: Response to Price et al. and Canuso et al.Konstantinos N Fountoulakis, Athanasios Saitis, Alan F Schatzberg
The American Journal of Psychiatry. 2025-10-01 - Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.Alan F Schatzberg, Konstantinos N Fountoulakis
The American Journal of Psychiatry. 2025-10-01
Journal Articles
- Splice-Break: Exploiting an RNA-Seq Splice Junction Algorithm to Discover Mitochondrial DNA Deletion Breakpoints and Analyses of Psychiatric DisordersFrancis S Lee, Alan F Schatzberg, Jack D Barchas, Virginia Kimonis, Elizabeth C Chao, Nucleic Acids Research
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
- American Psychiatric Association PublishingAlan Schatzberg, MD, National Institutes of Health
Press Mentions
After Quitting Antidepressants, Some People Suffer Surprising, Lingering SymptomsJuly 9th, 2025- ORYZON to Host Virtual KOL Event on July 9, 2025June 25th, 2025
- ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) PatientsJune 23rd, 2025
- Join now to see all
Grant Support
- The Career Development Institute for PsychiatryUNIVERSITY OF PITTSBURGH AT PITTSBURGH2011–2027
- A Biobehavioral research Training ProgramSTANFORD UNIVERSITY1994–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
